ATR Inhibitors in Platinum-Resistant Ovarian Cancer

SIMPLE SUMMARY: Platinum-resistant ovarian cancer (PROC) is a deadly cancer with a poor prognosis. Some drugs targeting ATR have shown initial success in the treatment of PROC. Therefore, we reviewed the mechanism of the ATR pathway, the results of preclinical and clinical trials in PROC, and potentially susceptible patients to ATR inhibitors. This study provides a basis for future experimental design and research. ABSTRACT: Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC.